ARTICLE | Clinical News
TT-223: Completed Phase II enrollment
February 9, 2009 8:00 AM UTC
Transition completed enrollment of about 80 patients in a double-blind, placebo-controlled, U.S. Phase II trial evaluating subcutaneous TT-223 given once daily. Eli Lilly licensed exclusive rights to ...